Capricor Therapeutics (CAPR) closed at $9.53 on November 13, 2026, down 6.9% from the previous close, on volume of 3,533,389 shares (30-day average 3,394,312).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 20, 2026 | Call Spread | 18-Dec-2615 : 20 C | 10,312 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Fri, 13-Nov 3:10 PM ET)
Capricor Therapeutics (CAPR) Receives a Buy from B. Riley Securities
TipRanks (Thu, 12-Nov 3:15 AM ET)
TipRanks (Thu, 12-Nov 1:01 AM ET)
Capricor jumps as Jones upgrades ahead of FDA decision on lead asset
Seeking Alpha News (Wed, 11-Nov 1:39 PM ET)
Piper Sandler Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)
TipRanks (Wed, 11-Nov 8:36 AM ET)
Cantor Fitzgerald Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)
TipRanks (Wed, 11-Nov 8:15 AM ET)
Oppenheimer Reaffirms Their Buy Rating on Capricor Therapeutics (CAPR)
TipRanks (Wed, 11-Nov 8:15 AM ET)
TipRanks (Wed, 11-Nov 7:10 AM ET)
Capricor Therapeutics shares rise as FDA decision nears
Seeking Alpha News (Tue, 10-Nov 9:08 PM ET)
Capricor Therapeutics GAAP EPS of -$0.73 misses by $0.31
Seeking Alpha News (Tue, 10-Nov 4:14 PM ET)
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Capricor Therapeutics trades on the NASDAQ stock market under the symbol CAPR.
As of November 13, 2026, CAPR stock price declined to $9.53 with 3,533,389 million shares trading.
CAPR has a beta of -0.16, meaning it tends to be less sensitive to market movements. CAPR has a correlation of 0.00 to the broad based SPY ETF.
CAPR has a market cap of $554.06 million. This is considered a Small Cap stock.
Last quarter Capricor Therapeutics reported $0 in Revenue and -$.73 earnings per share. This fell short of revenue expectation by $-10 million and missed earnings estimates by -$.28.
In the last 3 years, CAPR traded as high as $40.37 and as low as $2.80.
The top ETF exchange traded funds that CAPR belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
CAPR has outperformed the market in the last year with a price return of +65.2% while the SPY ETF gained +13.4%. CAPR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +126.4% and +49.4%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
CAPR support price is $9.45 and resistance is $11.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAPR shares will trade within this expected range on the day.
